Here's an excerpt: "Having the drug approved for the less severe patients was supposed to help Amarin take market share from GlaxoSmithKline, but now it appears Amarin will have to wait until the outcomes trial concludes in a few years.
Read all about it! Amarin is toast!!
http://www.fool.com/investing/general/2013/11/22/fda-to-amarin-no-appeal-for-you.aspx
Read all about it! Amarin is toast!!
http://www.fool.com/investing/general/2013/11/22/fda-to-amarin-no-appeal-for-you.aspx